Calculators for the assessment of need for drugs in oncology: justification of necessity and comparative characteristics

Petrovsky A.V.; Amosova V.A.; Tumenko E.E.; Linnik S.A.; Obukhova O.V.; Andramonova I.O.; Tryakin A.A.

doi:https://doi.org/10.17116/medtech2021430119

Petrovsky A.V.

Blokhin National Medical Cancer Research Center;
Sechenov First Moscow State Medical University

Amosova V.A.

Blokhin National Medical Cancer Research Center

Tumenko E.E.

Semashko National Research Institute of Public Healthcare

Linnik S.A.

Semashko National Research Institute of Public Healthcare;
«Marketnavigator» LLC

Obukhova O.V.

Central Research Institute for Organization and Informatization of Health Care

Andramonova I.O.

Central Research Institute for Organization and Informatization of Health Care

Tryakin A.A.

Blokhin National Medical Cancer Research Center;
Loginov Moscow Clinical Scientific and Practical Center

Calculators for the assessment of need for drugs in oncology: justification of necessity and comparative characteristics

Authors:

Petrovsky A.V., Amosova V.A., Tumenko E.E., Linnik S.A., Obukhova O.V., Andramonova I.O., Tryakin A.A.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2021;43(1): 9‑21

DOI: 10.17116/medtech2021430119

Read: 8032 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Petrovsky AV, Amosova VA, Tumenko EE, Linnik SA, Obukhova OV, Andramonova IO, Tryakin AA. Calculators for the assessment of need for drugs in oncology: justification of necessity and comparative characteristics. Medical Technologies. Assessment and Choice. 2021;43(1):9‑21. (In Russ.)
https://doi.org/10.17116/medtech2021430119

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Organization and payment for molecular genetic analysis in patients with certain malignancies in the constituent entities of the Russian Federation. Medical Technologies. Assessment and Choice. 2025;(1):36-50

Lung tuberculosis and malignant neoplasms: the current state of the problem. Russian Journal of Preventive Medicine. 2025;(3):122-127

Algorithms for morphological diagnostics of dysplastic nevus. P.A. Herzen Journal of Oncology. 2025;(2):83-88

The structure of causes of death of the adult population of the Moscow region in 2019 and 2023. Russian Journal of Archive of Pathology. 2025;(3):40-48

Dynamics of the main indicators of medical care to the population of the Russian Federation for the period 1993—2023 in the “Oncology” profile. P.A. Herzen Journal of Oncology. 2025;(3):71-77

Assessment of the oncological component of the adult’s population medical examination: the specialists’ opinion. Russian Journal of Preventive Medicine. 2025;(7):15-21

Selection of a plastic material for the replacement of facial skin defects in oncology patients. P.A. Herzen Journal of Oncology. 2025;(4):102-106

Ethmoid labyrinth cancer with extension into the orbital cavity. Russian Bulletin of Otorhinolaryngology. 2025;(4):119-122

Results of testing an antioxidant gel film for the prevention and treatment of palmar-plantar syndrome in cancer patients. P.A. Herzen Journal of Oncology. 2025;(5):59-63

New analgesics in oncology. Tafalgin employed as an alternative to opioid analgesics. P.A. Herzen Journal of Oncology. 2025;(5):73-77

Abstract:

Malignancies comprise one of the most important social and economic problems faced by modern society. Significant funds are planned to be invested to increase the volume of cancer therapy, especially for purchase of anticancer drugs, under the National Project “Fight against cancer”. For many years, drug procurement has been justified empirically (regardless the number of patients, stages of disease, cancer progression). Oncological service of the Russian Federation is faced with the problem of using these funds. In this regard, special calculators have been developed to calculate the need and the total cost of the required antineoplastic drug therapy. Among the tasks assigned to the calculators are such as estimation of the required drugs; drug distribution and combinations of therapy depending on funding sources and conditions of medical care; calculation of the required financing in general, for purchasing the drugs, etc. The authors describe 3 the most relevant calculators, identify their advantages and disadvantages and discuss the possible ways for improving of this methodology. However, it is necessary to validate continuously the available calculated data via comparison with real clinical practice in different regions. Moreover, constant work on updating the calculators based on modern clinical guidelines is essential.

Keywords:

cancer

oncology calculators

antineoplastic pharmacotherapy

demand planning

expenditures

Authors:

Petrovsky A.V.

Blokhin National Medical Cancer Research Center;
Sechenov First Moscow State Medical University

Amosova V.A.

Blokhin National Medical Cancer Research Center

Tumenko E.E.

Semashko National Research Institute of Public Healthcare

Linnik S.A.

Semashko National Research Institute of Public Healthcare;
«Marketnavigator» LLC

Obukhova O.V.

Central Research Institute for Organization and Informatization of Health Care

Andramonova I.O.

Central Research Institute for Organization and Informatization of Health Care

Tryakin A.A.

Blokhin National Medical Cancer Research Center;
Loginov Moscow Clinical Scientific and Practical Center

Received:

24.12.2020

Accepted:

12.01.2021

Close metadata

References:

Zlokachestvennye novoobrazovaniya v Rossii v 2018 godu (zabolevaemost’ i smertnost’). Pod red. Kaprina A.D., Starinskogo V.V., Petrovoj G.V. M.: MNIOI im. P.A. Gercena — filial FGBU «NMIRC» Minzdrava Rossii; 2018. (In Russ.).
Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2018 godu. Pod red. Kaprina A.D., Starinskogo V.V., Petrovoi G.V. M.: MNIOI im. P.A. Gercena — filial FGBU «NMIRC» Minzdrava Rossii; 2019. (In Russ.).
Kontsevaya AV, Balanova YuA, Myrzakmatova AO, et al. Economic damage of oncological diseases associated with modifiable risk factors. Analiz riska zdorov’yu. 2020;1:133-141. (In Russ.). https://doi.org/10.21668/health.risk/2020.1.15
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136(5):359-386. https://doi.org/10.1002/ijc.29210
Alexandrescu DT. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatology Online Journal. 2009;15(11):1. Accessed January 16, 2021. https://escholarship.org/uc/item/53f8q915
Advanced Melanoma. The Real Cost of Australian’s National Cancer. Accessed January 16, 2021. https://www.melanomapatients.org.au/wp-content/uploads/MPA_the_real_cost.pdf
Lichtenberg FR. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000—2009. Economics and Human Biology. 2014;13:107-127. https://doi.org/10.1016/j.ehb.2013.04.002
Lichtenberg FR. The impact of therapeutic procedure innovation on hospital patient longevity: evidence from Western Australia, 2000—2007. Social Science and Medicine. 2013;77:50-59. https://doi.org/10.1016/j.socscimed.2012.11.004
Lichtenberg FR, Pettersson B. The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997—2010: evidence from longitudinal, disease-level data. Economics of Innovation and New Technology. 2013;23(3):239-273. https://doi.org/10.1080/10438599.2013.828456
Lichtenberg FR, Tatar MC, Çalışkan Z. The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999—2010. Health Policy. 2014;117(3):361-373. https://doi.org/10.1016/j.healthpol.2014.06.002
Lichtenberg FR. The impact of pharmaceutical innovation on disability days and the use of medical services in the United States, 1997—2010. Journal of Human Capital. 2014;8(4):432-480.
Lichtenberg FR. The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010. Applied Health Economics and Health Policy. 2015;13(2):207-222. https://doi.org/10.1007/s40258-014-0144-3
Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;100(1):44-52. https://doi.org/10.1002/cncr.11859
Garin AM. Endokrinnaya terapiya i gormonozavisimye opuholi. M.: Triada; 2005. (In Russ.).
Abraham J, Staffurth J. Hormones in Cancer. Practical Clinical Oncology. Ed. by Hanna I., et al. Cambridge: Cambridge University Press; 2010.
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. New England Journal of Medicine. 2005;353(16):1673-1684. https://doi.org/10.1056/NEJMoa052122
Slamon DJ, Eiermann W, Robert NJ, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients: BCIRG006 study. Cancer Research. 2009;69(24 suppl):62. https://doi.org/10.1158/0008-5472.SABCS-09-62
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine. 2005;353(16):1659-1672. https://doi.org/10.1056/NEJMoa052306
Smith I, Procter M, Gelber RD, et al. 2-Year follow up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 2007;369(9555):29-36. https://doi.org/10.1016/S0140-6736(07)60028-2
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-489. https://doi.org/10.1038/nature10673
Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews. Clinical Oncology. 2013;10(10):588-598. https://doi.org/10.1038/nrclinonc.2013.153
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2017;377(14):1345-1356. https://doi.org/10.1056/NEJMoa1709684
Siu LL, Steeghs N, Meniawy T, et al. Preliminary results of a phase 1/2a study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor-related gene [GITR] agonist) alone and in combination with nivolumab in pts with advanced solid tumors. Journal of Clinical Oncology. 2017;35(15 suppl):104. https://doi.org/10.1200/JCO.2017.35.15_suppl.104
Perez RP, Riese JM, Lewis KD, et al. Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204. Journal of Clinical Oncology. 2017;35(15 suppl):3003.
Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology. 2015;16(4):375-384. https://doi.org/10.1016/S1470-2045(15)70076-8
Feinstein AJ, Long J, Soulos PR, et al. Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Affairs (Project Hope). 2015;34(4):592-600. https://doi.org/10.1377/hlthaff.2014.1119
Avxentyeva MV, Fedyanin MYu, Petrovsky AV, et al. Metodicheskie rekomendacii po ispol’zovaniyu v medicinskih organizaciyah kliniko-statisticheskih grupp dlya oplaty medicinskoj pomoshchi bol’nym so zlokachestvennymi novoobrazovaniyami. M. 2019. (In Russ.).
Avxentyeva MV, Omelyanovskiy VV, Petrovskiy AV, et al. New Approaches to the Development of Diagnostic Related Groups for Cancer Pharmacotherapy in Russian Federation. Medicinskie tekhnologii. Ocenka i vybor. 2018;32(2):8-22. (In Russ.). https://doi.org/10.31556/2219-0678.2018.32.2.008-022
Gordeev SS, Avxentyeva MV, Ledovskikh YuA., et al. Inpatient care: the evolution of payment methods and their impact on quality. Prakticheskaya onkologiya. 2020;21(2):91-100. (In Russ.).